Fabrice Smieliauskas

Fabrice Smieliauskas

Title

Assistant Professor

Department

Pharmacy Practice & Economics

Phone

313-577-1696

Email

fsmiel@wayne.edu

Fabrice Smieliauskas

Degrees and Certifications

  • Ph.D., Health Policy (Economics), Harvard University, Cambridge, MA (2011)
  • M.A., Economics, University of Toronto, Toronto, ON (2001)
  • B.Sc., Mathematics and Economics, University of Toronto, Toronto, ON (2000)

Positions and Employment

Academic Appointments

  • 2019-present: Assistant Professor, Department of Economics, Wayne State University
  • 2019-present: Assistant Professor, Department of Pharmacy Practice, Wayne State University
  • 2011-2019: Assistant Professor, Department of Public Health Sciences, University of Chicago
Center Appointments
  • 2012-2019: Faculty Affiliate, Center for Health and the Social Sciences, University of Chicago
  • 2012-2019: Member, University of Chicago Comprehensive Cancer Center
External Appointments
  • 2014- present: Alliance for Clinical Trials in Oncology: Member of Cancer Care Delivery Research, Symptom Intervention, Health Outcomes, Prevention, Community Oncology, Health Disparities, and Cancer in the Older Adult Committees

Recent Publications

Refereed Journal Articles

(*denotes joint first authors)
 
Other publications
  • 2018: President’s Cancer Panel. 2018. Promoting Value, Affordability, and Innovation in Cancer Drug Treatment. A Report to the President of the United States from the President’s Cancer Panel. Bethesda (MD): President’s Cancer Panel. https://prescancerpanel.cancer.gov/report/drugvalue/. My research presented in the report.
  • 2016: National Academies of Sciences, Engineering and Medicine. Implementation of lung cancer screening: Proceedings of a workshop. Washington, DC: The National Academies Press. doi: 10.172216/23680. https://www.nap.edu/catalog/23680/implementation-of-lung-cancer-screening-proceedings-of-a-workshop. My research presented in the report.
  • 2004: Felt-Lisk, S., G. Mays, L. Harris, M. Lee, R. Nyman, and F. Smieliauskas. Evaluation of HRSA’s Clinical Pharmacy Demonstration Projects. Princeton, NJ: Mathematica Policy Research. 
  • 2004: Chollet, D., R. Nyman, and F. Smieliauskas. Factors That Drive Health Care Costs in Indiana. Princeton, NJ: Mathematica Policy Research.
  • 2004: Verdier, J., S. Felt-Lisk, F. Smieliauskas, J. Wong, and L. Felland. Quality-Related Provider and Member Incentives in Medicaid Managed Care Organizations. Princeton, NJ: Mathematica Policy Research.
  • 2003: Chollet, D., F. Smieliauskas, and M. Konig. Mapping Health Insurance Markets, 2001: Structure and Change. Princeton, NJ:  Mathematica Policy Research. http://www.statecoverage.org/files/Mapping%20State%20Health%20Insurance%20Markets%202001%20-%20Structure%20and%20Change.pdf

Media Coverage

Research Funding

Current

  • 8/19-7/25: NCI UG1 CA189823. PI: J. Buckner. My role: co-I. “Alliance NCORP Research Base”. 
  • 12/18–11/23: NCI R01 CA225647. PI: Y.-C. T. Shih. My role: co-I. “Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications”. 
  • 11/17–3/20: NCI P30 CA014599. PI: M. Le Beau. My role: co-I. “No Smoker Left Behind.”

Past

  • 9/14–6/19: NCI UG1 CA189823. PI: J. Buckner. My role: co-I. “Alliance NCORP Research Base”. 
  • 3/16–1/18: NCATS UL1 TR000430. PI: F. Smieliauskas. My role: PI. “A Comparison of Single Level Anterior Cervical Discectomy and Fusion to Posterior Cervical Foraminotomy in the Treatment of Cervical Radiculopathy: A National Perspective with Long Term Follow-up.” 
  • 1/16–12/17: CHAS Seed Award. PI: F.Smieliauskas. My role: PI. “Racial disparities in Predictive Biomarkers, Access to Precision Medicine, and Cancer Outcomes”. 
  • 4/14–3/16: NCI R03 CA184986. PI: F. Smieliauskas. My role: PI. “Capacity constraints and disparities in the scale-up of lung cancer CT screening”. 
  • 1/13–6/15: Cancer Research Foundation Young Investigator Award. PI: F. Smieliauskas. My role: PI. Title: "Off-label Drug Use in Oncology: Policy, Unintended Consequences, and Comparative Effectiveness". 
  • 8/13–7/14: AHRQ R01 HS018535. PI: Y.-C. T. Shih. My role: Co-Investigator. Title: “Monoclonal Antibodies in Cancer Care: Is Underinsurance an Access Barrier?”. 
  • 12/12–2/14: ACS #IRG 58-004. PI: F. Smieliauskas. My role: PI. Title: "Off-label drug use in oncology: policy and unintended consequences for clinical research". 
  • 12/11–11/12: ACS #IRG 58-004. PI: F. Smieliauskas. My role: PI. Title: "The role of sponsorship in clinical oncology research: evidence from clinicaltrials.gov". 
  • 5/11–4/14: NIH U01 GM087729. PI: D. Lauderdale. My role: Co-Investigator. Title: “Modeling MRSA in the Community”. 
  • 7/07–6/10: NIH T32 AG00186. PI: D. Wise. My role: Pre-Doctoral Fellow in Health & Aging at the National Bureau of Economic Research. 
  • 9/07–8/09: SSHRC Doctoral Fellowship.
  • 9/05–8/06: AHRQ T32 HS000055. PI: J. Newhouse. My role: Doctoral Fellow.  

Professional Memberships

  • 2018-present: International Society for Pharmacoeconomics and Outcomes Research
  • 2018-present: Society for Medical Decision Making
  • 2014-present: American Society of Clinical Oncology
  • 2011, 2015, 2018-present: American Economic Association
  • 2008-present: American Society of Health Economists

Departmental / University Service

  • 2019-present: Undergraduate Committee, Department of Economics, Wayne State University 

Editor / Reviewer

  • 2019-present: Editorial Board, Medical Care Research and Review
  • 2014: Full grant proposal reviewer, Robert Wood Johnson Foundation’s (RWJF) Public Health Services and Systems Research (PHSSR) program
  • 2010-present: Referee for Journal of Health Economics, Pharmacoeconomics, Value in Health, Health Services Research, Medical Care Research and Review, Journal of the National Cancer Institute, Journal of the National Cancer Institute: Spectrum, The Oncologist, Journal of General Internal Medicine, Management Science